The investigational therapy gantenerumab significantly lowered levels of established biomarkers in a rare, inherited form of early-onset Alzheimer’s disease, despite failing to slow cognitive decline or memory loss in symptomatic and asymptomatic patients, according to data from a Phase 2/3 clinical trial. Based on these results, enrolled patients…
Following a positive review of preliminary data, an independent board recommended the Phase 2b/3 study investigating oral Anavex 2-73 (blarcamesine) in people with early Alzheimer’s disease continue without modification. As specified in trial protocol, the Independent Data Safety Monitoring Board (DSMB)…
Racial discrimination is a barrier to care in Alzheimer’s disease and dementia, according to two U.S. surveys conducted on behalf of the Alzheimer’s Association. This opinion was supported by more than one-third of Black Americans (36%), and nearly one-fifth of…
Cortexyme’s ongoing Phase 2/3 GAIN clinical trial, which is evaluating the investigational treatment COR388 (atuzaginstat) in people with mild to moderate Alzheimer’s disease, has been approved to continue as planned to…
BAN2401, an experimental treatment for Alzheimer’s disease (AD), will be tested in the new global AHEAD 3-45 clinical trial, its developers have announced. The Phase 3 study — to be conducted in the U.S., Canada, Japan,…
Anavex Life Sciences will expand its Phase 2b/3 clinical trial testing the efficacy and safety of Anavex 2-73 (blarcamesine) for the treatment of early Alzheimer’s disease into Canada and the United Kingdom (U.K.) following the go-ahead from…
An experimental vaccine targeting the toxic form of tau protein reduced cellular tangles in the brain — a hallmark of Alzheimer’s — and eased behavioral and motor defects in a mouse model of the disease, a study showed. By generating high levels of anti-tau antibodies, this vaccine…
Get regular updates to your inbox.